亚盛医药
亚盛医药官方号
老虎认证: 亚盛医药官方账号
IP属地:未知
0关注
2914粉丝
亚盛医药官方账号

【2025 EHA】亚盛医药核心产品耐立克®和APG-2575等13项进展入选2025年欧洲血液学协会年会

亚盛医药(纳斯达克代码:AAPG;香港联交所代码:6855)宣布,涉及公司原创1类新药奥雷巴替尼(商品名:耐立克®)、Bcl-2抑制剂APG-2575、EED抑制剂APG-5918等重磅品种的13项研究进展将在2025年6月12日至15日于意大利米兰举行的2025年欧洲血液学协会(EHA)年会上公布,其中包括1项口头报告,及多项壁报展示和线上发表。 EHA年会作为欧洲血液学领域规模最大的国际会议,每年吸引来自全球100多个国家的1万多名专业人士与会,分享全球最前沿的研究进展和突破性临床数据。 口头报告(Oral) Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy 整合基因组和转录组学见解以预测接受三代TKI治疗的CML患者的疗效和结局 摘要编号:S162 分会场:CML治疗疗效及耐药的生物学(Biology of CML treatment response and resistance) 报告时间:北京时间6月14日,周六,晚上23:30-23:45(欧洲中部时间6月14日,周六,下午17:30-17:45) 主要作者:北京大学人民医院江倩教授,北京大学人民医院张小帅 壁报展示(Poster) Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospe
【2025 EHA】亚盛医药核心产品耐立克®和APG-2575等13项进展入选2025年欧洲血液学协会年会

亚盛医药美股纳斯达克上市暨15周年庆典举行

来源:苏州日报 今年1月24日,亚盛医药在美股纳斯达克上市,成功融资1.42亿美元。2月15日,亚盛医药美股纳斯达克上市暨15周年庆典在苏州总部举行。市委副书记、市长吴庆文,亚盛医药董事长、CEO杨大俊出席。 亚盛医药成立15年来,始终坚持创新引领,致力于解决未被满足的临床需求,已成为国内顶尖、全球领先的创新药企业。近年来,亚盛医药加速全球化布局,创造了多个首单并成功登陆纳斯达克,成为国内少数港美两地上市的创新药企,此次上市也是中国创新药从本土创新走向全球价值输出的标志性事件和中国生物医药行业国际化进程中的重要里程碑。杨大俊说,企业将坚定专注创新,真正践行“解决中国乃至全球患者尚未被满足的临床需求”的使命,加速推进产品管线的开发进度,用临床数字赢得市场,让亚盛产品造福更多全球患者。 日前,亚盛医药位于苏州的全球产业基地获得江苏省药品监督管理局批准的新的药品生产许可证,包括A证、B证和C证,是苏州小分子创新药第一家获得ABC三证的企业,并通过了药品GMP符合性检查,满足全球临床和中国商业化供药需求,企业全产业链能力得以进一步提升。现场举行了药品生产许可证授证仪式。 市政府秘书长俞愉,苏州工业园区和市有关部门负责同志参加活动。
亚盛医药美股纳斯达克上市暨15周年庆典举行
avatar亚盛医药
2022-04-18

【患者招募】亚盛医药Bcl-2抑制剂APG-2575关键注册Ⅱ期临床研究受试者招募

受试者招募 现有一项“APG-2575单药治疗复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的有效性和安全性的单臂关键注册II 期临床研究”正在开展并招募受试者。 入组条件 本研究已获得国家药品监督管理总局批准并通过各参与研究中心伦理委员会的审核,如果您符合以下条件,将有机会参加本项临床研究: ● 复发或难治慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL) ● BTK抑制剂和免疫化疗均难治、复发、或不耐受;或:一线BTK抑制剂治疗失败且不适合免疫化疗 ● 年龄≥ 18岁,男性或非妊娠非哺乳期女性 ● 能够理解并自愿签署书面知情同意书 ● 自愿参加并能完成研究程序和随访检查 还需满足其他研究要求,如果您同意参加研究,研究医生将对您是否满足其他要求进行评估。 不需要为研究药物和本研究要求的检测、检查支付费用。 如果您满足以上条件且有意参加或有兴趣进一步了解该项研究更多信息,请联系:18907327297(马盼盼)
【患者招募】亚盛医药Bcl-2抑制剂APG-2575关键注册Ⅱ期临床研究受试者招募
avatar亚盛医药
2022-06-12

EHA 2022|Ascentage Releases Results of Lisaftoclax in R/R NHL

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released results from a Phase I study of the company’s novel Bcl-2-selective inhibitor lisaftoclax (APG-2575) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL) at the 2022 European Hematology Association Hybrid Congress (EHA 2022). The EHA Congress is the largest gathering of the hematology field in Europe. It showcases the most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from more than 100 countries every year. Lisaftoclax Bcl-2-selective inhibitor  Lisaftoclax is a novel, orally administere
EHA 2022|Ascentage Releases Results of Lisaftoclax in R/R NHL
avatar亚盛医药
2022-05-22

EHA2022|Ascentage to Present Clinical Data of Lisaftoclax in NHL

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release the latest results from a Phase I study of lisaftoclax (APG-2575), the company’s novel Bcl-2 selective inhibitor, in Chinese patients with relapsed/refractory non-Hodgkin lymphomas (r/r NHLs) at the 2022 European Hematology Association Hybrid Congress (EHA 2022), making it the company’s first appearance at the EHA Congress. The EHA Congress is the largest gathering of the hematology field in Europe. It showcases most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from over 100 countries every year. This year, the EHA
EHA2022|Ascentage to Present Clinical Data of Lisaftoclax in NHL
avatar亚盛医药
2022-09-29

Excerpts from MD Anderson Video Remarks on the World CML Day

This year’s World CML Day coincided with the recent publication of clinical data of olverembatinib (HQP1351) in the prestigious oncology journal, the Journal of Hematology & Oncology. Prof. Hagop Kantarjian, Chairman of the Department of Leukemia at MD Anderson Cancer Center, shared his thoughts on the eve of World CML Day. Click to watch the below video from Prof. Kantarjian. September 22nd was chosen as the date of the World CML Day because Chronic Myeloid Leukemia (CML) is a disease driven by the BCR-ABL fusion gene induced by the translocation of human chromosome 9 and 22. Recently, results from a Phase I/II study of olverembatinib in patients with CML were published in the prestigious oncology journal, the Journal of Hematology & Oncology. The publication of these results
Excerpts from MD Anderson Video Remarks on the World CML Day
avatar亚盛医药
2022-09-29

【文汇报】国际慢粒日丨一名慢粒患者的七年:生死面前,奋力“定格幸运”

曾有一位教授说,“如果一定要生肿瘤,情愿是慢粒。”慢粒白血病,慢性白血病中最常见的一种类型,占成人白血病的15%。随着第一代靶向治疗药物的出现,慢粒白血病被称为“最幸运的白血病”,10年生存率高达85%-90%,实现和常人一样生存。数据之下,个体与疾病的搏击、新药的诞生、医生的努力、家庭的迷茫与坚持交织在一起,呈现着数据难以承载的生命张力。 9月22日是国际慢粒日,听一名85后慢粒患者说确诊故事,七年时间仿佛是在“不幸”与“幸运”之间折返跑。对这个小家庭而言,生死面前一切反而变得纯粹,就是要奋力“定格幸运”。 【本文转载自文汇报】 图源:图虫 01 哈尔滨的夏,一家人的心情降至冰点 没察觉到什么身体异样,于洋是在退伍归来工作七八年后,被确诊为慢粒的。 “当时,是单位例行体检,发现我的白细胞增高很多,体检的医院让我去复查,正常人的白细胞指标在4-10之间,我当时是20多,翻倍了。”于洋记得前往医院复查后,白细胞指标依旧很高,医生让住院接受骨穿等一系列检查。等一系列检查结果出来,他确诊了——是慢粒。 这是2013年的夏天,于洋28岁,拿着诊断报告,虽是哈尔滨的夏天,一家人的心情降到了冰点。 “以前没听说过这病,非常恐惧、迷茫。”出院后的于洋开始服用羟基脲维持治疗,“吃了一段羟基脲后,感觉血常规都正常了,就没怎么吃药了。” 大约一年后,于洋发现身体上的异样,总感觉没有力气,“当时也不知道是脾脏肿大,还当胃治,后来到了血液科,医生说是脾脏肿大,然后一查白细胞已经300多了。”于洋原以为吃羟基脲可以把血常规指标调整好,就没事了,直到脾脏出现问题、白细胞“严重超标”,他才知道这是不够的,“正规治疗”这才起步。 那是2014年的七八月,于洋住院了,继续服用羟基脲,并开始吃国产仿制靶向药。 于洋是不幸的,年纪轻轻确诊白血病。中国慢粒患者发病较西方更为年轻化,流行病学调查显示,中国慢粒患者的
【文汇报】国际慢粒日丨一名慢粒患者的七年:生死面前,奋力“定格幸运”
avatar亚盛医药
2022-04-27

Ascentage to  Present Data from Seven Studies at ASCO 2022

Ascentage Pharma (6855.HK) today announced that updated results from seven studies involving the company’s five novel drug candidates will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will present clinical trials involving the third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351); as well as the following investigational agents: (1) Bcl-2 inhibitor lisaftoclax (APG-2575); (2) MDM-p53 inhibitor alrizomadlin (APG-115); (3) ALK inhibitor APG-2449; and (4) dual Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252). The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the cl
Ascentage to  Present Data from Seven Studies at ASCO 2022
avatar亚盛医药
2022-06-08

Ascentage Releases Updated Results of Lisaftoclax in R/R CLL/SLL

Ascentage Pharma (6855.HK) today announced that it has released the updated results from a Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax (APG-2575) in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) in a Poster Presentation at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting. Entering the fifth consecutive year in which company’s abstracts were selected for presentations by the ASCO Annual Meeting, Ascentage Pharma showcased results from multiple clinical trials of its five drug candidates, including favorable data of lisaftoclax, a key drug candidate of the company’s apoptosis-targeted pipeline, in Chinese patients with R/R CLL/SLL showing an objective response rate (ORR) of 67.4%. Lisaftoclax was well tole
Ascentage Releases Updated Results of Lisaftoclax in R/R CLL/SLL
avatar亚盛医药
2023-08-08

Global Registrational Phase III Study of APG-2575 Cleared by FDA

Ascentage Pharma (6855.HK) announced today that lisaftoclax (APG-2575), a novel Bcl-2 inhibitor and one of the company’s core assets, has been cleared by the US Food and Drug Administration (FDA) to enter a global registrational Phase III study for treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were BTKi previously treated . This clearance marks a major step-forward in the global development of lisaftoclax and another important milestone following the approval by the Center for Drug Evaluation (CDE) in China for the registrational Phase II study of lisaftoclax (APG-2575) in patients with relapsed/refractory CLL/SLL (R/R CLL/SLL) in December 2021, as it could potentially pave the way for lisaftoclax to become the second Bcl-2 inhibitor
Global Registrational Phase III Study of APG-2575 Cleared by FDA
avatar亚盛医药
2022-09-29

【大咖寄语】国际慢粒日,MD Anderson癌症中心白血病科主任Hagop Kantarjian教授有话说

近期,奥雷巴替尼(耐立克®)的临床进展在国际著名肿瘤学术期刊Journal of Hematology&Oncology上发表。恰逢国际慢粒日,全球著名血液肿瘤专家、MD Anderson癌症中心白血病科主任Hagop Kantarjian教授从美国发来视频寄语。 观看下方视频,感受来自大洋彼岸的期盼! 慢粒,全称为慢性粒细胞白血病,也被称为慢性髓细胞白血病。其致病原因是患者体内第9号和22号染色体发生了相互易位,导致该易位形成了新的基因——BCR-ABL融合基因,这也是每年的9月22日被定为国际慢粒日的由来。 曾经,慢粒也被认为是一种“不治之症”,但是,随着靶向BCR-ABL的酪氨酸激酶抑制剂(TKI)问世,慢粒的治疗格局被改变。一代和二代BCR-ABL抑制剂让慢粒成为像高血压、糖尿病一样的“慢性病”,慢粒患者得以和正常人一样长期生存,并且回归工作、回归生活。 尽管慢粒白血病已经发展为可以治疗、控制甚至治愈的慢性病,患者依旧被笼罩在巨大的“耐药”阴霾之下。BCR-ABL激酶区突变是获得性耐药的重要机制,其中T315I突变是最常见的耐药突变类型。伴有T315I突变的慢粒患者对目前所有一代、二代BCR-ABL抑制剂均耐药。 在亚盛医药原创的第三代BCR-ABL抑制剂耐立克®上市前,中国伴T315I突变耐药慢粒患者长期面临无药可医的困境,而在全球层面,尽管已有药物获批使用,但因药物可及性、药物相关不良事件等原因,耐药慢粒的治疗仍然存在未被完全满足的临床需求。 近期,耐立克®治疗耐药慢粒的I期和II期临床研究结果在国际著名肿瘤学术期刊Journal of Hematology&Oncology上发表,进一步验证了该品种在慢粒患者中的持久疗效和安全性。这意味着中国创新药有望惠及全球慢粒患者,亦向全世界展示了中国的创新能力和学术实力。 恰逢国际慢粒日,全球著名血液肿瘤专家、MD An
【大咖寄语】国际慢粒日,MD Anderson癌症中心白血病科主任Hagop Kantarjian教授有话说
avatar亚盛医药
2022-07-21

Study of Olverembatinib in Refractory CML/ALL Approved in Canada

Ascentage Pharma (6855.HK) today announced that the Phase Ib study of Ascentage Pharma’s novel drug candidate, olverembatinib (HQP1351), for the treatment of patients with refractory chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has been approved by Health Canada, making it Ascentage Pharma’s first clinical study in the country. This open-label, multicenter, randomized, global Phase Ib study is designed to evaluate the safety, efficacy, pharmacokinetics (PK) and determine the recommended Phase II dose (RP2D) of olverembatinib in patients with CML in chronic-phase (CP), accelerated-phase (AP), or blast-phase (BP) or with Ph+ ALL, who are resistant or intolerant to at least two tyrosine kinase inhibitors (TKIs). CML is a hematologic
Study of Olverembatinib in Refractory CML/ALL Approved in Canada
avatar亚盛医药
2023-03-12

Ascentage Declares No Business Dealings with Silicon Valley Bank

In light of the recent closure of Silicon Valley Bank, Ascentage Pharma Group International (the “Company” or “Ascentage Pharma”) would like to state that, since the Company’s incorporation, the Company has not had any business dealings with Silicon Valley Bank or its affiliates. In addition, as at the date of this announcement, the Company has not placed any deposit with Silicon Valley Bank or its affiliates. About Ascentage Pharma Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics
Ascentage Declares No Business Dealings with Silicon Valley Bank
avatar亚盛医药
2022-06-08

Ascentage Releases Results of FAK/ALK/ROS1 inhibitor APG-2449

Ascentage Pharma (6855.HK) today announced that it has released the results from its Phase I first-in-human (FIH) study of the company’s novel FAK inhibitor and third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) APG-2449 in patients with second-generation TKI-resistant ALK/ROS1+ non-small-cell lung cancer (NSCLC) or mesothelioma in a Poster Presentation at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting. APG-2449 is the first China-developed third-generation ALK inhibitor entering clinical studies. Entering the fifth consecutive year in which its abstracts were selected for presentations by the ASCO Annual Meeting, Ascentage Pharma showcased results from multiple clinical trials of its five drug candidates, including the first-time results of APG-2449 highlighti
Ascentage Releases Results of FAK/ALK/ROS1 inhibitor APG-2449
avatar亚盛医药
2022-06-07

Ascentage Releases Updated Results of Alrizomadlin+Pembrolizumab

Ascentage Pharma (6855.HK) today announced that it has released the updated results from a Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) plus pembrolizumab in adults and children with various solid tumors in a Poster Discussion session at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting. Entering the fifth consecutive year in which its abstracts were selected for presentations by the ASCO Annual Meeting, Ascentage Pharma showcased results from multiple clinical trials of its five drug candidates, including the much-anticipated data of alrizomadlin plus pembrolizumab, updated from the data at last year’s oral presentation at the ASCO Annual Meeting. The updated results further validate the combination therapy’s efficacy in patients with immuno-oncologic
Ascentage Releases Updated Results of Alrizomadlin+Pembrolizumab
avatar亚盛医药
2022-11-26

亚盛医药全球产业基地获生产许可证,并将开启创新工场

亚盛医药(6855.HK)宣布,“踔厉前行,创新致盛”——首届亚盛创新药高质量发展生态峰会暨亚盛医药全球产业基地及创新工场启用仪式今日在苏州圆满举办,标志着公司又迎来新的重大里程碑。 在本次活动上,除了亚盛医药全球产业基地及创新工场启用仪式的隆重举办,盛禾众创空间揭牌、首批入驻企业签约、中国药科大学国际商学院就业基地挂牌等系列仪式相继举行。 苏州市委副书记、市长吴庆文,苏州市政府秘书长俞愉,国家专利局专利审查协作江苏中心副主任孙跃飞,苏州工业园区党工委副书记、管委会主任林小明,苏州市工信局局长万利,苏州市市场监督管理局局长钱斌,苏州市医保局局长施燕萍,江苏省药监局苏州检查分局局长、苏州审评核查分中心主任王琳琳女士等领导出席并见证了此次庆典。 吴庆文表示:“当前苏州正深入学习贯彻党的二十大精神,加快实施创新驱动发展战略,加快实现高水平科技自立自强。生物医药是苏州举全市之力重点培育的‘一号产业’,近年来苏州持之以恒聚焦新药研发、高端医疗器械、生物技术及新型疗法等三大重点领域,全力打造国际一流生物医药创新策源地、世界级生物医药产业地标核心区。 亚盛医药是我市优秀生物医药企业的代表,期待亚盛医药以本次活动为新的起点,继续扎根苏州、创新发展,为我市生物医药产业发展树立新的标杆、增添新的动力。苏州将继续秉持亲商服务理念,不断强化政策支撑、完善配套设施、做优人才服务,着力构建原始创新、技术创新、产业创新齐头并进的良好局面,助力包括亚盛医药在内的生物医药创新企业加速成长壮大,携手打造苏州生物医药产业的美好明天。” 全球产业基地启航,转型全产业链企业 继2021年12月亚盛医药全球总部、研发中心在苏州启用,公司又迎来重大里程碑,全球产业基地宣告正式起航。 亚盛医药日前通过现场核查、并获准核发药品生产企业许可证(A证),是公司全产业链发展的一个重要里程碑。该证为2022年度苏州市生物医药企业所
亚盛医药全球产业基地获生产许可证,并将开启创新工场
avatar亚盛医药
2022-01-06

Ascentage to Present at 2022 J.P. Morgan Healthcare Conference

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th Annual J.P. Morgan Healthcare Conference. Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma, will present at the conference on January 10th, 2022 at 9:00-9:25 AM ET (10:00-10:25 PM China Standard Time). The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry. The 40th Conference will take place virtually from January 10th through January 13th, 2022, ET. The webcast of the presentation can be listened at the link below. https://jpmorgan.metameetings.net/events/healthcare22/sessions/403
Ascentage to Present at 2022 J.P. Morgan Healthcare Conference
avatar亚盛医药
2024-08-22

一图读懂 | 亚盛医药2024年中期业绩

undefined
一图读懂 | 亚盛医药2024年中期业绩

去老虎APP查看更多动态